NOTE 12 - SEGMENT INFORMATION

6 Months Ended

Oct. 31, 2022

Notes

NOTE 12 - SEGMENT INFORMATION

NOTE 12 - SEGMENT INFORMATION

The following information is presented in accordance with ASC Topic 280, "Segment Reporting", for the three and six months ended October 31, 2022 and 2021; we accounted for two reportable business segments - (1) natural sweetener (stevioside), and (2) corporate and other pharmaceutical. Our reportable segments are strategic business units that offer different products and are managed separately based on the fundamental differences in their operations. Condensed financial information with respect to these reportable business segments for the three and six months ended October 31, 2022 and 2021 is as follows: 

- 14 -

	Three Months Ended October 31,		Six Months Ended October 31,
	2022	2021	2022	2021
Revenues:
Stevioside	$7,305,077	$10,001,477	$ 14,912,400	$16,163,155
Corporate and other	98,185	106,647	200,765	213,429
Total segment and consolidated revenues	$7,403,262	$10,108,124	$15,113,165	$16,376,584
Interest expense:
Stevioside	$(124,622)	$(119,934)	$(257,643)	$(190,605)
Corporate and other	-	-	-	-
Total segment and consolidated interest expense	$(124,622)	$(119,934)	$(257,643)	$(190,605)
Depreciation and amortization:
Stevioside	$281,571	$312,038	$573,745	$623,881
Corporate and other	37,537	56,349	77,891	112,942
Total segment and consolidated depreciation and amortization	$ 319,108	$368,387	$ 651,636	$736,823
Income (loss) from operations before income taxes:
Stevioside	$(318,921)	$(1,941,725)	$(573,852)	$(2,753,962)
Corporate and other	59,270	48,952	120,050	111,072
Total loss from operations before income taxes	$(259,651)	$(1,892,773)	$(453,802)	$(2,642,890)

	October 31, 2022	April 30, 2022
Segment property and equipment:
Stevioside	$4,873,051	$5,854,328
Corporate and other	1,399,063	1,631,405
Total property and equipment	$6,272,114	$7,485,733